[1] Schroeder H, Werner M, Meyer DR, et al.Low-dose paclitaxel-coated versus uncoated percutaneous transluminal balloon angioplasty for femoropopliteal peripheral artery disease: one-year results of the ILLUMENATE European randomized clinical trial (randomized trial of a novel paclitaxel-coated percutaneous angioplasty balloon)[J]. Circulation,2017,135(23):2227-2236.
[2] Ott I, Cassese S, Groha P, et al. ISAR-PEBIS (paclitaxe-leluting balloon versus conventional balloon angioplasty for in-stent restenosis of superficial femoral artery): a randomized trial[J]. J Am Heart Assoc,2017,6(7).pii: e006321.
[3] Ott I, Cassese S, Groha P, et al.Randomized comparison of paclitaxel-eluting balloon and stenting versus plain balloon plus stenting versus directional atherectomy for femoral artery disease(ISAR-STATH)[J]. Circulation,2017, 135(23):2218-2226.
[4] Krishnan P, Faries P, Niazi K, et al.Stellarex drug-coa-ted balloon for treatment of femoropopliteal disease: twelve-month outcomes from the randomized ILLUMENATE pivotal and pharmacokinetic studies[J]. Circulation,2017,136(12):1102-1113.
[5] Kinstner CM, Lammer J, Willfort-Ehringer A, et al.Paclitaxel-eluting balloon versus standard balloon angioplasty in in-stent restenosis of the superficial femoral and proximal popliteal artery: 1-year results of the PACUBA trial[J]. JACC Cardiovasc Interv,2016,9(13):1386-1392.
[6] Jia X, Zhang J, Zhuang B, et al.Acotec drug-coated balloon catheter: randomized, multicenter, controlled clinical study in femoropopliteal arteries: evidence from the Aco-Art Ⅰ trial[J]. JACC Cardiovasc Interv,2016,9(18):1941-1949.
[7] Tepe G, Laird J, Schneider P, et al.Drug-coated balloon versus standard percutaneous transluminal angioplasty for the treatment of superficial femoral and popliteal peri-pheral artery disease 12-month results from the IN. PACT SFA randomized trial[J]. Circulation,2015,131(5):495-502.
[8] Scheinert D, Duda S, Zeller T, et al.The LEVANT Ⅰ (Lutonix paclitaxel-coated balloon for the prevention of femoropopliteal restenosis) trial for femoropopliteal revascularization: first-in-human randomized trial of low-dose drug-coated balloon versus uncoated balloon angioplasty[J]. JACC Cardiovasc Interv,2014,7(1):10-19.
[9] Liistro F, Grotti S, Porto I, et al.Drug-eluting balloon in peripheral intervention for the superficial femoral artery The DEBATE-SFA randomized trial (drug eluting balloon in peripheral intervention for the superficial femoral artery)[J]. JACC Cardiovasc Interv,2013,6(12):1295-1302.
[10] Tepe G, Zeller T, Albrecht T, et al.Local delivery of paclitaxel to inhibit restenosis during angioplasty of the leg[J]. N Engl J Med,2008,358(7):689-699.
[11] Ohki T, Yokoi H, Kichikawa K, et al.Two-year analysis of the Japanese cohort from the Zilver PTX randomized controlled trial supports the validity of multinational cli-nical trials[J]. J Endovasc Ther,2014,21(5):644-653.
[12] Katsanos K, Spiliopoulos S, Kitrou P, et al.Risk of death following application of paclitaxel-coated balloons and stents in the femoropopliteal artery of the leg: a systema-tic review and meta-analysis of randomized controlled trials[J]. J Am Heart Assoc,2018,7(24):e011245.
[13] Schneider PA, Laird JR, Doros G, et al.Mortality not correlated with paclitaxel exposure: an independent patient-level meta-analysis of a drug-coated balloon[J]. J Am Coll Cardiol,2019,73(20):2550-2563.
[14] Secemsky EA, Kundi H, Weinberg I, et al.Association of survival with femoropopliteal artery revascularization with drug-coated devices[J]. JAMA Cardiol,2019.doi:10.1001
[15] Guo W. New DCB era for BTK: 6-months results from the China AcoArt Ⅱ Study. LINC2019. Leipzig, Germany[EB/OL].[2019-07-08]. https://linc2019.cncptdlx.com/media/0830_Wei_Guo_23_01_2019_Room_1_-_Main_Arena_1.pdf.
[16] Binder S. Evolution of taxanes in the treatment of metastatic breast cancer[J]. Clin J Oncol Nurs,2013,17 Suppl:9-14.
[17] TAXOL (paclitaxel) Injection Warnings and Safety Information. Bristol Myers-Squibb2011[EB/OL].[2019-07-08]. https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020262s049lbl.pdf.
[18] Otsuka F, Vorpahl M, Nakano M, et al.Pathology of se-cond-generation everolimus-eluting stents versus first-generation sirolimus- and paclitaxel-eluting stents in humans[J]. Circulation,2014,129(2):211-223.
[19] Duda SH, Bosiers M, Lammer J, et al.Drug-eluting and bare nitinol stents for the treatment of atherosclerotic lesions in the superficial femoral artery: long-term results from the SIROCCO trial[J]. J Endovasc Ther,2006,13(6):701-710.
[20] Duda SH, Bosiers M, Lammer J, et al.Sirolimus-eluting versus bare nitinol stent for obstructive superficial femoral artery disease: the SIROCCO Ⅱ trial[J]. J Vasc Interv Radiol,2005,16(3):331-338.
[21] Zeller T, Baumgartner I, Scheinert D, et al.Drug-eluting balloon versus standard balloon angioplasty for infrapopliteal arterial revascularization in critical limb ischemia: 12-month results from the IN.PACT DEEP randomized trial[J]. J Am Coll Cardiol,2014,64(15):1568-1576.
